Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Loa Loa (eye worm) | hypothetical protein | 0.00621234 | 1 | 1 |
Chlamydia trachomatis | sulfite reductase | 0.00401313 | 0.371693 | 0.5 |
Echinococcus granulosus | NADPH cytochrome P450 reductase | 0.00621234 | 1 | 1 |
Trypanosoma brucei | NADPH--cytochrome P450 reductase, putative | 0.00621234 | 1 | 0.5 |
Toxoplasma gondii | flavodoxin domain-containing protein | 0.00271212 | 0 | 0.5 |
Giardia lamblia | Hypothetical protein | 0.00569944 | 0.853467 | 0.5 |
Trypanosoma brucei | NADPH-cytochrome p450 reductase, putative | 0.00621234 | 1 | 0.5 |
Trypanosoma cruzi | p450 reductase, putative | 0.00621234 | 1 | 0.5 |
Leishmania major | p450 reductase, putative | 0.00621234 | 1 | 1 |
Trypanosoma cruzi | cytochrome P450 reductase, putative | 0.00621234 | 1 | 0.5 |
Loa Loa (eye worm) | FAD binding domain-containing protein | 0.00621234 | 1 | 1 |
Schistosoma mansoni | 5-methyl tetrahydrofolate-homocysteine methyltransferase reductase | 0.00401313 | 0.371693 | 0.371693 |
Trypanosoma brucei | NADPH--cytochrome P450 reductase, putative | 0.00621234 | 1 | 0.5 |
Trypanosoma brucei | NADPH-dependent diflavin oxidoreductase 1 | 0.00621234 | 1 | 0.5 |
Mycobacterium ulcerans | formate dehydrogenase H FdhF | 0.00621234 | 1 | 0.5 |
Leishmania major | NADPH-cytochrome p450 reductase-like protein | 0.00621234 | 1 | 1 |
Echinococcus multilocularis | NADPH dependent diflavin oxidoreductase 1 | 0.00621234 | 1 | 1 |
Schistosoma mansoni | cytochrome P450 reductase | 0.00621234 | 1 | 1 |
Trypanosoma cruzi | cytochrome P450 reductase, putative | 0.00621234 | 1 | 0.5 |
Giardia lamblia | Nitric oxide synthase, inducible | 0.00569944 | 0.853467 | 0.5 |
Plasmodium falciparum | nitric oxide synthase, putative | 0.00621234 | 1 | 0.5 |
Schistosoma mansoni | NADPH flavin oxidoreductase | 0.00350023 | 0.22516 | 0.22516 |
Echinococcus multilocularis | NADPH cytochrome P450 reductase | 0.00621234 | 1 | 1 |
Brugia malayi | FAD binding domain containing protein | 0.00621234 | 1 | 1 |
Brugia malayi | flavodoxin family protein | 0.00621234 | 1 | 1 |
Plasmodium vivax | NADPH-cytochrome p450 reductase, putative | 0.00621234 | 1 | 1 |
Trichomonas vaginalis | sulfite reductase, putative | 0.00621234 | 1 | 1 |
Echinococcus granulosus | NADPH dependent diflavin oxidoreductase 1 | 0.00621234 | 1 | 1 |
Toxoplasma gondii | flavodoxin domain-containing protein | 0.00271212 | 0 | 0.5 |
Trypanosoma cruzi | NADPH-dependent FMN/FAD containing oxidoreductase, putative | 0.00621234 | 1 | 0.5 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
Activity (functional) | NOVARTIS: Antimalarial liver stage activity measured as a greater than 50% reduction in Plasmodium yoelii schizont area in HepG2-A16-CD81 cells at 10uM compound concentration, determined by immuno-fluorescence. | ChEMBL. | 22096101 | |
EC50 (functional) | = 0.914 uM | W2 Pf proliferation inhibition | Novartis-GNF Malaria Box. | No reference |
EC50 (functional) | = 0.914 uM | NOVARTIS: Inhibition of Plasmodium falciparum W2 (drug-resistant) proliferation in erythrocyte-based infection assay | ChEMBL. | 18579783 |
EC50 (functional) | = 1.162 uM | PF proliferation inhibition 3D7 | Novartis-GNF Malaria Box. | No reference |
EC50 (functional) | = 1.162 uM | NOVARTIS: Inhibition of Plasmodium falciparum 3D7 (drug-susceptible) proliferation in erythrocyte-based infection assay | ChEMBL. | 18579783 |
IFI promiscuity index | = 0.15385 | IFI promiscuity index | Novartis-GNF Malaria Box. | No reference |
Species name | Source | Reference | Is orphan |
---|---|---|---|
Plasmodium falciparum | ChEMBL23 | 18579783 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.